Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders ...
PharmiWeb

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting

Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting·     New long-term data presented at AES 2025 ...

Xenon Pharmaceuticals Inc. (XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation Transcript

Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 ...
Fierce Pharma

Fast-rising UCB set to file for Fintepla approval in 3rd epileptic disorder after trial win

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...
BioSpace

Biogen, Stoke Boost Epilepsy Drug’s Blockbuster Potential With Early Seizure Reduction Data

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...

(PR) UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

The MarketWatch News Department was not involved in the creation of this content.-- Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a stati ...